Pharmaseed is proud to introduce our fast-growing new Anatomy Unit during the coming medical device & instrumentation conference, on September 26th at the Dan Carmel hotel, Haifa and the MDDMI conference on October 10th at the Haifa Congress center.
You are all invited to visit us at the conferences on booth number 27 at the medical device & instrumentation conference and booth number 48 at the MDDMI conference and get a first-hand impression.

May 2011

Visit us at our booth No. 65 in the ILSI BioMed 2011, the annual conference and exhibition of the Israeli life sciences industry, to be held at the David Intercontinental Hotel in Tel Aviv, Israel, between: 23-25 May 2011.

March 2011

CTS Europe 2011 conference in Maastricht


Dr. Lamensdorf, CEO, and Prof. Levy, CSO, presenting at the conference.	Israeli wine tasting at the CTS Europe 2011 conference in Maastricht, courtesy of PharmaSeed.

BIO-Europe Spring, Milan, Italy,
Pharmaseed exhibited at Bio Europe 2011 in Milan, Italy, a conference about partnering and scientific promotion.
Many visitors came to the Pharmaseed booth and many new business opportunities were explored.
http://www.ebdgroup.com/bes/program/index.php

IsraMed Tech, Haifa

Pharmaseed participated successfully at theIsraMedTech conference that took place 1-2 March 2011 at the Dan Carmel Hotel in Haifa.
Dr. Itschak lamensdorf, our CEO, took part in the Regulatory, Clinical, Pricing & Reimbursement Trial Affairs Panel discussion.
At the conference we launched our new collaboration with the Lahav Research Institute, which will enable us to supply a research package from in vitro through in vivo entailing small and large animal trials.
See: www.medevents.co.il/events/2

Cell Therapy Summit Europe 2011, Maastricht, The Netherlands,
March 10-11.
Pharmaseed delivered two lectures at The Summit in Maastricht, an industry-
focused leadership gathering in Europe for cell therapy:
Use of Stem Cell Therapy in Degenerative & Neurodegenerative Disorders:
Translational Animal Models
Discussion Leader: Dr. Itschak Lamensdorf, CEO, PharmaseedGetting an
Early Proof-of-Concept at the Preclinical Stage: Practical Considerations
Discussion Leader: Prof. Aharon (Ronnie) Levy, Scientific Director,
Pharmaseed
http://www.ctsconference.com/index.asp?mm=1

December 2010

PharmaSeed participated in the 19th Annual Meeting of the The Israel Society for Neuroscience (ISFN; http://www.isfn.org.il),Eilat, Israel, between 12-14 December 2010. The presentations were given by Dr Itschak Lamensdorf, CEO, PharmaSeed, titled: Use of stem cell therapy in neurodegenerative disorders; translational animal models, and Dr Revital Duvdevani, VP R&D, PharmaSeed, titled: Getting proof of concept in Parkinson's disease assessing cognitive functions as a new measurable translational clinical relevant endpoint.
Both abstracts can be found on ISFN website:
http://www.isfn.org.il/images/stories/abstracts-final.pdf

November 2010

PharmaSeed participated in the 2nd China Jiangsu Conference for International Technology
Transfer and Commercialization (CITTC; http://en.cittc.org), Nanjing, China, between 12-14 November 2010.
Dr Tomer Shemesh, BDM, Pharmaseed, and Mr Qi Shanlong, Head, Office of Administration, Yangzhou Rixing Bio-Tech Co Ltd, signed on a joint product development at the Signing Ceremony held at CITTC.
Integral to delivering cost-effective quality services to its clients, Pharmaseed has recently completed the construction of a BL-2 safety level Infectious Disease Unit. As such, Pharmaseed now offers integrated in-vitro and in-vivo models for a range of infectious diseases caused by either bacteria or viruses. The infectious disease unit is headed by Dr Judith Ben-Porath,
email: Judith@pharmaseedltd.com.

October 2010

PharmaSeed participated at the German-Israeli Life Sciences Committee (GILSC) meeting hosted by the Biotech Cluster Rhine-Neckar (www.biorn.org) in Heidelberg, Germany, between 03-05 October 2010. Approximately 70 representatives from over 30 biotechnology companies presented their firms and gave an overview about their areas of business. PharmaSeed's representatives Dr Itschak Lamensdorf, CEO, and Dr Tomer Shemesh, BDM, convened in one-to-one-meetings with potential business partners and discussed possible future cooperations.

Pharmaseed exhibited at the Biotechnica conference (www.biotechnica.de), a large scale event held in Hannover, Germany, between 05-07 October 2010.

September 2010
PharmaSeed's expert commentary on challenges that R&D pharma companies face in developing CNS-targeted drug compounds, published in Biopharma online biotechnology magazine (http://www.biopharma.co.il).

July 2010
PharmaSeed has recently entered into exclusive agreements with preclinical CROs and biology product development and supplier companies:

TISSUE SOLUTIONS, Scotland – a one-stop-shop of human biological materials, including human tissues and organs to the biopharma and medical device industries;
ADVANCELL, Spain – in-vitro bio-servicing company specializing in ADME and skin biology testing;
NEURO-ZONE, Italy – in-vitro/ vivo bio-servicing company and a producer of CNS primary cells;
PRECLIN BIOSYSTEMS, Switzerland – in vivo bio-servicing company specializing in infectious disease models;
CYTOCENTRICS, Germany – GLP accredited electrophysiology expert facility.

June 2010
Pharmaseed exhibited at ILSI BioMed 2010, the largest annual event of the Israeli life science industry, held at the David Inter Continental Hotel in Tel Aviv, Israel, between 14-16 June 2010.

March 2010
PharmaSeed participated in the Bio-Europe conference in Barcelona, Spain, between 08-10 March 2010.

November 2009
Pharmaseed presents at the Israel Society for Neuroscience’s 18th annual meeting at the Princess Hotel, Eilat, Israel, November 22-24. Abstracts of the meeting were published in the Journal of Molecular Neuroscience (volume 39, supplement 1, November 2009).

June 2009
Pharmaseed participates in BioMed 2009 , the flagship Israeli life sciences industry conference, at Tel Aviv's David InterContinental Hotel June 15-17. The company attracted broad interest from potential clients in Europe and the U.S.

July 2008
Collaboration with MINDGENIX –Pharmaseed and MINDGENIX, a New York-based company specializing in pre-clinical neuroscience contract research services, agree that Pharmaseed will manage MINDGENIX’s third-party testing business, which involves the testing of compounds using APP/PS1 transgenic mice. Pharmaseed will operate all aspects of the testing business, including invoicing and collecting client payments, and MINDGENIX will be entitled to receive a portion of the revenue earned by Pharmaseed. The term of the agreement is three years and is renewable every year for five years.

May 2008
Pharmaseed exhibits at BioMed 2008, the largest annual event of the Israeli life science industry, held May 27- 29 at the David InterContinental Hotel in Tel Aviv.

June 2007
Pharmaseed exhibits at BioMed 2007, the largest annual event of the Israeli life science industry, held June 5-7 at the David InterContinental Hotel in Tel Aviv.

January 2007
Pharmaseed and Lannet, a U.S.-based pharma company specializing in the manufacturing and distribution of generic drugs, agree to collaborate on the development of a new generic compound.

December 2006
Pharmaseed presents at the annual meeting of the Israel Society for Neuroscience (ISFN).

May 2006
Pharmaseed exhibits at BioMed 2006, the largest annual event of the Israeli life science industry, held May 29-31 at Jerusalem's International Convention Center.

March 2006
Pharmaseed and the Canadian pharmaceutical company AlphaRx initiate a collaborative project for analyzing the potential use of AlphaRx molecules for the treatment of CNS disorders.

December 2005
Pharmaseed and MIGAL - Galilee Technology Center initiate a collaborative project to develop a new neuroprotectant compound.

December 2005
Pharmaseed and the Israel-based biopharmaceutical company Kernel BioPharma initiate a collaborative project to develop and commercialize a CNS functional genomics program.